GLP-1 drugsIn silico
Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation
Value in Health
- Semaglutide
- GLP-1 and incretin signalling
- Cardiovascular disease
- Chronic kidney disease
- Metabolic dysfunction-associated steatohepatitis
- Humans
The paper
Don Husereau, Marc Evans, Julie Hviid Hahn-Pedersen, Soeren Mattke
Show 6 more authors
Robert King, Jamie Kettle, Bejamin D. Bray, Marina Berger, Maria Luckevich, Christopher Lübker,University of Ottawa · University of Southern California
Value in Health · 29 Sep 2026